Peptic ulcer Medical Services in China

Peptic ulcer disease (PUD) refers to a break or sore in the mucosal lining of the stomach (gastric ulcer) or the first part of the small intestine (duodenal ulcer). These lesions result from an imbalance between aggressive factors—primarily gastric acid and pepsin—and the protective mechanisms of the mucosa, including mucus secretion, bicarbonate production, epithelial cell renewal, and adequate mucosal blood flow. The two dominant etiologies are infection with Helicobacter pylori (H. pylori), present in over 90% of duodenal ulcers and 70–80% of gastric ulcers, and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase-1 (COX-1) and impair prostaglandin-mediated mucosal defense. Less common causes include Zollinger-Ellison syndrome, Crohn’s disease, malignancy (e.g., gastric adenocarcinoma or lymphoma), severe physiological stress (e.g., ICU patients with critical illness), and smoking—though smoking does not initiate ulcers, it impairs healing and increases recurrence risk. Epidemiologically, PUD affects approximately 5–10% of the global population at some point in life, with higher prevalence in older adults and in regions with limited access to H. pylori eradication therapy. In China, age-standardized incidence is estimated at 120–180 cases per 100,000 person-years, with duodenal ulcers more common than gastric ulcers (ratio ~3:1). Key modifiable risk factors include NSAID use (especially without gastroprotection), smoking, heavy alcohol consumption, untreated H. pylori infection, and prolonged psychological stress—though stress alone is not causative. Uncomplicated ulcers may cause intermittent epigastric pain (often burning or gnawing), bloating, early satiety, nausea, or hematemesis/melena if bleeding occurs. Complications—including gastrointestinal hemorrhage, perforation, gastric outlet obstruction, and malignant transformation (rare in duodenal ulcers but relevant in gastric ulcers)—significantly increase morbidity and mortality. Quality of life impact is substantial: chronic pain disrupts sleep, work productivity, dietary habits, and mental health; recurrent symptoms lead to anxiety about complications and frequent healthcare utilization; and long-term proton pump inhibitor (PPI) dependence may raise concerns about nutrient absorption (e.g., magnesium, vitamin B12) and bone health. Early diagnosis via upper endoscopy—gold standard for visualization, biopsy, and H. pylori testing—is essential to differentiate benign ulcers from malignancy and guide targeted therapy. With appropriate management, most ulcers heal within weeks and recurrence rates drop dramatically after successful H. pylori eradication.

Peptic ulcer disease (PUD) refers to mucosal defects in the stomach (gastric ulcers) or duodenum (duodenal ulcers) that extend through the muscularis mucosae into the submucosa. The pathogenesis centers on an imbalance between aggressive luminal factors—primarily gastric acid and pepsin—and defensive mucosal mechanisms, including mucus-bicarbonate secretion, epithelial restitution, mucosal blood flow, and prostaglandin-mediated cytoprotection.

The most common cause of peptic ulcer is infection with Helicobacter pylori, a gram-negative, microaerophilic bacterium that colonizes the gastric mucosa. H. pylori induces chronic active gastritis, disrupts tight junctions, impairs bicarbonate secretion, and stimulates gastrin release—leading to hyperchlorhydria in duodenal ulcer patients. Its virulence factors (e.g., CagA, VacA) promote inflammation, oxidative stress, and apoptosis, ultimately compromising mucosal integrity. Eradication of H. pylori heals ulcers and reduces recurrence rates from >60% to <5% annually.

Nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin—even at low doses—are the second leading cause. NSAIDs inhibit cyclooxygenase-1 (COX-1), diminishing prostaglandin E2 and I2 synthesis, which are critical for maintaining mucosal blood flow, mucus production, and epithelial repair. COX-2 selective inhibitors confer lower but non-negligible ulcer risk, particularly in high-risk patients. Concurrent use of NSAIDs with corticosteroids, anticoagulants, or SSRIs further amplifies ulcer risk.

Other pharmacologic triggers include bisphosphonates (especially oral formulations), potassium chloride tablets, and chemotherapeutic agents (e.g., fluorouracil), which can cause direct mucosal injury when improperly administered or retained. Smoking is a well-established modifiable risk factor: it delays ulcer healing, increases recurrence, reduces mucosal blood flow, impairs bicarbonate secretion, and enhances gastric acid output. Alcohol consumption—particularly in excess—is associated with acute gastric mucosal injury and may exacerbate ulcer formation in susceptible individuals, though its role as an independent cause remains less definitive than for H. pylori or NSAIDs.

Genetic factors contribute modestly to susceptibility. First-degree relatives of patients with duodenal ulcers exhibit higher prevalence of H. pylori infection and increased risk of ulcer development, suggesting shared environmental exposure and possible genetic predisposition. Polymorphisms in genes regulating immune response (e.g., IL-1β, TNF-α, TLR4) influence inflammatory severity upon H. pylori infection; IL-1β variants are linked to hypochlorhydria and gastric atrophy—predisposing to gastric ulcers and gastric cancer. ABO blood group O is associated with increased duodenal ulcer risk, possibly due to enhanced H. pylori adhesion to gastric epithelium expressing H1 antigen.

Environmental and behavioral determinants significantly modulate risk. Socioeconomic status correlates inversely with H. pylori prevalence—early-life crowding, poor sanitation, and limited access to clean water increase acquisition risk. Chronic psychological stress does not directly cause ulcers but may impair mucosal defense via autonomic dysregulation (e.g., reduced vagal tone, splanchnic vasoconstriction) and hypothalamic-pituitary-adrenal axis activation, potentially worsening outcomes in established disease. Shift work, sleep deprivation, and circadian disruption may alter gastric motility and acid secretion patterns, though evidence remains observational. Dietary factors (e.g., spicy foods, caffeine) do not cause ulcers but may provoke dyspeptic symptoms and delay symptom resolution.

Less common causes include Zollinger–Ellison syndrome (gastrin-secreting neuroendocrine tumors causing profound hypergastrinemia and acid hypersecretion), systemic mastocytosis, Crohn’s disease involving upper GI tract, and vasculitides such as granulomatosis with polyangiitis. Critical illness—especially in ICU settings—can precipitate stress-related mucosal damage (Curling’s ulcers post-burn, Cushing’s ulcers post-head trauma), mediated by splanchnic hypoperfusion, ischemia-reperfusion injury, and impaired mucosal defense.

In summary, peptic ulceration arises predominantly from H. pylori infection and NSAID exposure, with modulation by host genetics, lifestyle behaviors (smoking, alcohol), environmental hygiene, and comorbid conditions. Comprehensive evaluation must therefore integrate microbiologic testing, medication history, endoscopic assessment, and individualized risk stratification to guide targeted therapy and prevention.

Peptic ulcer disease (PUD) refers to a break in the mucosal lining of the stomach (gastric ulcer) or duodenum (duodenal ulcer), extending through the muscularis mucosae into the submucosa. It results from an imbalance between aggressive factors—primarily gastric acid and pepsin—and defensive mechanisms, including mucus-bicarbonate secretion, epithelial restitution, prostaglandin-mediated mucosal blood flow, and tight intercellular junctions. The most common etiologies are *Helicobacter pylori* infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs); less frequent causes include Zollinger-Ellison syndrome, systemic mastocytosis, Crohn’s disease, and malignancy-associated ulcers.

Early symptoms of peptic ulcer are often subtle and nonspecific, leading to delayed recognition. Patients may report intermittent epigastric discomfort described as a dull, burning, or gnawing sensation, typically occurring 1–3 hours after meals or during fasting—especially at night. This postprandial or nocturnal pattern is more characteristic of duodenal ulcers, whereas gastric ulcers often cause pain shortly after eating due to acid contact with the ulcerated gastric mucosa. Early-stage dyspepsia may be mistaken for functional gastrointestinal disorder; however, unlike functional dyspepsia, ulcer-related discomfort tends to be partially relieved by antacids or food ingestion (particularly in duodenal ulcers) but may worsen with certain foods (e.g., spicy, acidic, or caffeinated items). Mild nausea, early satiety, and occasional bloating may also occur, though these lack diagnostic specificity.

Typical symptoms reflect established mucosal injury and include persistent, localized epigastric pain that follows a chronic, recurrent course—often lasting weeks to months with spontaneous remissions and exacerbations. Pain intensity varies but is usually moderate and not sharp or colicky. Duodenal ulcers classically present with hunger pain or nocturnal pain that awakens the patient between midnight and 3 a.m., alleviated within minutes by food or antacids. Gastric ulcers tend to produce pain 30–60 minutes postprandially, sometimes associated with vomiting or anorexia. In older adults and NSAID users, ulcer presentation may be atypical or entirely asymptomatic—up to 25% of patients with documented ulcers are asymptomatic until complications arise.

Accompanying symptoms frequently co-occur and support clinical suspicion. These include hematemesis (bright red or coffee-ground vomitus), melena (tarry, foul-smelling stools), and iron-deficiency anemia manifesting as fatigue, pallor, exertional dyspnea, or palpitations—indicative of chronic occult bleeding. Anorexia and unintentional weight loss are more common in gastric ulcers and raise concern for malignancy. Nausea and vomiting may occur, particularly if the ulcer is located near the gastric outlet or induces reflex gastric stasis. Rarely, patients report referred pain to the back (suggesting posterior duodenal ulcer penetration) or radiation to the right scapula (associated with high gastric ulcers).

Complications represent critical manifestations requiring urgent intervention. Upper gastrointestinal bleeding is the most common complication, presenting as overt (hematemesis/melena) or occult (positive fecal immunochemical test, unexplained iron deficiency). Perforation—full-thickness breach of the wall—causes sudden, severe, generalized abdominal pain with board-like rigidity, rebound tenderness, and absent bowel sounds; upright chest X-ray may reveal free intraperitoneal air. Penetration occurs when the ulcer erodes into adjacent structures (e.g., pancreas, liver, biliary tree), causing persistent, deep, boring pain unrelieved by standard therapy and potentially mimicking pancreatic or biliary pathology. Gastric outlet obstruction results from edema, spasm, or fibrotic scarring near the pylorus or duodenal bulb, leading to recurrent postprandial vomiting (often voluminous and containing undigested food), early satiety, epigastric distension, and weight loss; physical exam may reveal succussion splash. Malignant transformation is rare in benign ulcers but warrants vigilance: gastric ulcers with irregular margins, nodular bases, or failure to heal after 8–12 weeks of appropriate therapy must undergo rigorous endoscopic evaluation and biopsy to exclude adenocarcinoma.

Diagnosis relies on a combination of clinical assessment and objective testing. Upper gastrointestinal endoscopy (esophagogastroduodenoscopy, EGD) remains the gold standard: it allows direct visualization, precise localization, characterization (size, shape, base, margins), and targeted biopsy to rule out malignancy or confirm *H. pylori*. Rapid urease testing, histology, and culture can be performed on biopsy specimens. Non-invasive *H. pylori* testing includes urea breath test (high sensitivity/specificity), stool antigen assay (excellent for initial diagnosis and post-treatment confirmation), and serology (limited utility due to inability to distinguish past vs. active infection). Serum gastrin levels are indicated if Zollinger-Ellison syndrome is suspected (e.g., refractory ulcers, multiple ulcers, diarrhea, hypersecretion). Imaging modalities such as upper GI series with barium contrast have largely been supplanted by endoscopy but may still identify ulcers as龛影 (niche defects) and associated deformities—though they lack biopsy capability and sensitivity for small or flat lesions.

Differential diagnosis is essential to avoid misattribution. Functional dyspepsia shares overlapping symptoms (epigastric pain, bloating, early satiety) but lacks objective mucosal injury on endoscopy and shows no response to ulcer-healing therapy. Gastroesophageal reflux disease (GERD) presents with retrosternal burning, regurgitation, and acid brash—pain rarely localizes to the epigastrium alone and is typically exacerbated by recumbency or bending. Chronic pancreatitis may mimic ulcer pain with steady, boring epigastric or back pain, steatorrhea, and elevated pancreatic enzymes or imaging abnormalities. Gastric or duodenal malignancy must always be excluded, especially in older patients, smokers, or those with alarm features (weight loss, anemia, vomiting, age >55 at first presentation). Other considerations include eosinophilic gastroenteritis, lymphoma, ischemic gastropathy (in elderly or vascular disease), and medication-induced mucosal injury (e.g., bisphosphonates, potassium chloride, mycophenolate). Cardiac angina may rarely refer to the epigastrium—particularly in diabetics or women—and requires electrocardiographic and cardiac biomarker evaluation when clinical suspicion exists. Accurate diagnosis hinges on integrating symptom chronology, risk factor profile, physical findings, and timely endoscopic evaluation.

Peptic ulcer disease (PUD) refers to mucosal defects in the stomach or duodenum extending through the muscularis mucosae, most commonly caused by Helicobacter pylori infection or nonsteroidal anti-inflammatory drug (NSAID) use. Management is stratified according to etiology, severity, complications (e.g., bleeding, perforation, obstruction), and patient comorbidities. Treatment goals include symptom relief, ulcer healing, eradication of underlying causative factors, prevention of recurrence, and mitigation of complications.

Conservative treatment forms the cornerstone of uncomplicated PUD management. It emphasizes lifestyle modification and risk factor mitigation. Patients are advised to discontinue NSAIDs whenever clinically feasible; if ongoing anti-inflammatory therapy is essential, co-prescription of a proton pump inhibitor (PPI) is mandatory. Smoking cessation is strongly recommended, as tobacco impairs mucosal blood flow, delays ulcer healing, and increases recurrence risk by up to 2-fold. While dietary restrictions are no longer evidence-based for routine ulcer healing, patients should avoid irritants that exacerbate symptoms—such as excessive caffeine, alcohol, and spicy foods—on an individualized basis. Stress reduction techniques may support adherence and symptom control but are not substitutes for pharmacologic therapy. Bed rest is unnecessary; however, activity modification during acute symptomatic phases may improve comfort.

Pharmacologic therapy is central to PUD management and follows evidence-based protocols. First-line treatment for H. pylori-positive ulcers is quadruple therapy: a high-dose PPI (e.g., esomeprazole 40 mg twice daily), bismuth subsalicylate 524 mg four times daily, tetracycline 500 mg four times daily, and metronidazole 500 mg three or four times daily—all administered for 10–14 days. In regions with low clarithromycin resistance (<15%), standard triple therapy (PPI + amoxicillin 1 g twice daily + clarithromycin 500 mg twice daily for 14 days) remains an option, though efficacy has declined globally. For NSAID-induced ulcers without H. pylori, high-dose PPI monotherapy (e.g., omeprazole 40 mg once daily or esomeprazole 40 mg once daily) for 4–8 weeks is standard. Healing rates exceed 90% at 8 weeks. Histamine-2 receptor antagonists (H2RAs) such as famotidine 40 mg twice daily are less effective than PPIs and reserved for mild cases or short-term symptom control. Sucralfate (1 g four times daily) may be used adjunctively in select patients intolerant to PPIs, though it lacks antimicrobial activity and does not prevent recurrence. Maintenance therapy is generally unnecessary after confirmed healing and eradication unless patients require long-term NSAIDs or have recurrent ulcers; in such cases, low-dose PPI prophylaxis is indicated.

Surgical intervention is now rare—reserved for life-threatening complications unresponsive to endoscopic or medical management. Indications include hemodynamically unstable upper gastrointestinal bleeding refractory to endoscopic hemostasis (e.g., visible vessel, spurting), free perforation with peritonitis, gastric outlet obstruction due to fibrotic stenosis unrelieved by endoscopic balloon dilation, or suspicion of malignancy in non-healing gastric ulcers. Procedures include laparoscopic or open oversewing of perforations, partial gastrectomy (Billroth I or II) for refractory bleeding or obstruction, and vagotomy (rarely performed today due to superior medical alternatives). Endoscopic interventions—including epinephrine injection, thermal coagulation, hemoclip placement, and over-the-scope clip (OTSC) deployment—are first-line for active bleeding and achieve definitive hemostasis in >90% of cases. Surgery carries higher morbidity (wound infection, anastomotic leak, dumping syndrome) and mortality (2–5% in elderly/comorbid patients) compared to endoscopic or medical approaches and is thus employed only when minimally invasive options fail.

Treatment in China offers distinct advantages rooted in integrated clinical infrastructure, national guideline harmonization, and technological adoption. The Chinese Society of Gastroenterology (CSG) publishes regularly updated, locally validated consensus guidelines incorporating regional antibiotic resistance patterns—particularly critical given China’s high metronidazole (>70%) and clarithromycin (>25%) resistance rates. This enables empiric regimens with >90% eradication success. Nationwide endoscopy networks ensure rapid access to high-definition white-light and image-enhanced endoscopy (e.g., narrow-band imaging, linked-color imaging), facilitating precise ulcer characterization, early malignancy detection, and real-time therapeutic intervention. Artificial intelligence–assisted endoscopic diagnosis systems—deployed across tier-1 hospitals—improve detection sensitivity for subtle lesions and post-eradication mucosal changes. Moreover, China’s centralized pharmaceutical procurement system ensures affordability and consistent availability of generic PPIs, bismuth compounds, and antibiotics, reducing treatment abandonment. Multidisciplinary ulcer clinics integrating gastroenterology, pathology, microbiology, and nutrition services optimize longitudinal care, particularly for complex or recurrent cases.

Recovery advice emphasizes structured follow-up and sustained behavioral adherence. All patients with gastric ulcers must undergo repeat endoscopy after 8–12 weeks to confirm healing and exclude malignancy—a mandatory step in China’s gastric cancer screening cascade. H. pylori eradication must be verified via urea breath test, stool antigen test, or biopsy-based histology at least 4 weeks after completing antibiotics and off PPIs for ≥2 weeks. Patients should avoid NSAIDs for at least 8 weeks post-healing; if reinitiation is unavoidable, concurrent PPI prophylaxis is non-negotiable. Alcohol intake should be limited to ≤14 units/week, and smoking cessation counseling with pharmacotherapy (varenicline or nicotine replacement) should be offered. Nutritional support includes small, frequent meals to reduce gastric distension and avoidance of late-night eating to minimize nocturnal acid breakthrough. Symptom diaries help identify triggers and assess treatment response. Long-term surveillance is advised for patients with chronic NSAID use, prior complicated ulcers, or familial gastric cancer history. With appropriate management, >95% of uncomplicated ulcers heal within 8 weeks, and recurrence rates fall below 10% at 1 year following successful H. pylori eradication and NSAID discontinuation.